NSE filing, NSE: AARTIDRUGS. Summary written from the filing by ALFA Finder's alert engine.
Aarti Drugs Ltd: key numbers
- Share price
- ₹446.05
- Market cap
- ₹4,071 Cr
- Revenue (annual)
- ₹2,565 Cr
- Net profit (annual)
- ₹194.9 Cr
- P/E (TTM)
- 17.8×Sector 42.0×
- Promoter holding
- 54.07%-0.36% QoQ
- FII holding
- 2.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Drugs Ltd
All →Aarti Drugs Business Update
Aarti Drugs disclosed that the US FDA inspected its subsidiary Pinnacle Life Science's Baddi plant on 2-6 November 2026 and issued three Form 483 observations. The company states there is no financial or operational impact.
Aarti Drugs Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 826.2 Cr (+27% YoY), EBITDA Rs 137.9 Cr (16.6% margin, +370 bps), PAT Rs 82.8 Cr (+83%). Specialty chemicals nearly doubled; formulations grew 58%.
Aarti Drugs Results Update
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Aarti Drugs Q2 FY27 Results: Net Profit ₹82.8 Cr, Up 83.2% YoY
Aarti Drugs Ltd reported revenue from operations of ₹826.2 Cr (+26.6% YoY) and net profit of ₹82.8 Cr (+83.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹82.8 Cr · +83.2% YoY
Aarti Drugs Board Meeting Date
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
Aarti Drugs Other Announcement
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Other board meeting outcome announcements
All →BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.
Voltas Board Meeting Outcome
Voltas Limited's board approved Deloitte Haskins & Sells as statutory auditors for five years from the 73rd AGM, replacing SRBC & Co. LLP, whose second and final term ends at that AGM. Subject to shareholder approval.
- Execution
- Five years: financial years 2027-28 to 2031-32 (from the 73rd AGM in 2027 to the 78th AGM in 2032)
CMX Holdings Board Meeting Outcome
Riwind Green Energy (formerly CMX Holdings) board approved altering its MOA main objects into six consolidated objects and a postal ballot notice. The change refocuses the company on solar, EPC, battery storage and renewable data-centre businesses.
Sahajanand Medical Technologies Board Meeting Outcome
Sahajanand Medical Technologies' board appointed M/s Amit Jaste & Associates as Secretarial Auditor for FY 2026-27 to FY 2030-31. The appointment is subject to shareholder approval.
- Execution
- FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval
Gretex Corporate Services Board Meeting Outcome
Gretex Corporate Services re-appointed Arvind Harlalka, Alok Harlalka and Rajiv Kumar Agarwal as directors after a board meeting. Terms are 60 months, effective from April 2027 and May 2027.
- Execution
- 60 months
Rajasthan Cylinders & Containers Board Meeting Outcome
Rajasthan Cylinders' board approved unaudited results for the quarter and half year ended September 30, 2026. The filing contains no financial figures.